LEO Pharma has reported impressive growth in 2025, driven by strategic product launches and an acquisition that strengthens its dermatology portfolio.
Target Overview
LEO Pharma, a prominent global player in the dermatology sector, has demonstrated impressive revenue growth and significant improvements in profitability and free cash flow during the first nine months of 2025. The company has successfully launched Anzupgo® in the U.S., gaining momentum in the market rapidly since its September release. This launch reflects LEO Pharma's dedication to fostering innovation and expanding patient access to care.
In Q3 2025, LEO Pharma reported a revenue increase of 7%, amounting to DKK 10,064 million, with a notable organic growth contributing to this success. The surge in revenue can largely be attributed to the performance of its Strategic brands, particularly Adtralza®/Adbry® and Anzupgo®, which saw substantial growth in their sales figures.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Denmark
Denmark's pharmaceutical landscape is recognized for its innovative approaches and strong research and development capabilities. The country ranks high in global healthcare standards, with substantial investm
Similar Deals
Philip Morris International → Fertin Pharma
2023
LEO Pharma
invested in
Spevigo®
in 2025
in a Other deal
Disclosed details
Revenue: $1M
EBITDA: $0M
Net Income: $0M